Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: The 'common arm' approach

Expert Review of Anticancer Therapy

Volumn 12, Issue 12, 2012, Pages 1591-1596

  Mack, Philip C ^a   Gandara, David R ^a   Lara, Primo N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

clinical trials; common arm; globalization; lung cancer; pharmacogenomics

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; TIRAPAZAMINE;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; FEBRILE NEUTROPENIA; GENOTYPE; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENOMICS; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; REVIEW; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; INTERNATIONALITY; JAPAN; LUNG NEOPLASMS; PHARMACOGENETICS; RESEARCH DESIGN; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; UNITED STATES;

EID: 84871504787     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.135     Document Type: Review

References (20)

1. Malinowski HJ, Westelinck A, Sato J, Ong T. Same drug, different dosing: Differences in dosing for drugs approved in the United States, Europe, and Japan. J. Clin. Pharmacol. 48(8), 900-908 (2008
2. Arnold FL, Kusama M, Ono S. Exploring differences in drug doses between Japan and western countries. Clin. Pharmacol. Ther. 87(6), 714-720 (2010
3. Thiers FA, Berndt AR. From the analyst's couch: Trends in the globalization of clinical trials. Nat. Rev. Drug Dis. 7, 13-14 (2008
4. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095-2103 (2000
5. Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with nonsmall- cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22(9), 1589-1597 (2004
6. Maruyama R, Nishiwaki Y, Tamura T et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J. Clin. Oncol. 26(26), 4244-4252 (2008
7. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br. J. Cancer 91(Suppl. 2), S18-S23 (2004
8. Camus P. Interstitial lung disease in patients with non-small-cell lung cancer: Causes, mechanisms and management. Br. J. Cancer 91(Suppl. 2), S1-S2 (2004
9. Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br. J. Cancer 99(11), 1757-1762 (2008
10. Gandara DR, Kawaguchi T, Crowley J et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A model for assessing population-related pharmacogenomics. J. Clin. Oncol. 27(21), 3540-3546 (2009
11. Noda K, Nishiwaki Y, Kawahara M et al.; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346(2), 85-91 (2002
12. Lara PN Jr, Gandara DR, Natale RB. Randomized Phase III trial of cisplatin/ irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin. Lung Cancer 7(5), 353-356 (2006
13. Lara PN Jr, Chansky K, Shibata T et al Common arm comparative outcomes analysis of Phase 3 trials of cisplatin +irinotecan versus cisplatin + etoposide in extensive stage small-cell lung cancer: Final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer 116(24), 5710-5715 (2010
14. Sekine I, Nokihara H, Yamamoto N et al. Common arm analysis: One approach to develop the basis for global standardization in clinical trials of non-small-cell lung ancer. Lung Cancer 53(2), 157-164 (2006
15. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A Phase III trial - INTACT 2. J. Clin. Oncol. 22(5), 785-794 (2004
16. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A Phase III trial-INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004
17. Georgoulias V, Ardavanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A Phase III randomized trial. J. Clin. Oncol. 23(13), 2937-2945 (2005
18. Ohe Y, Ohashi Y, Kubota K et al. Randomized Phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann. Oncol. 18(2), 317-323 (2007
19. Kawahara M. Phase III randomized study of vinorelbine, gemcitabine followed by docetaxel versus paclitaxel and carboplati in patients with advanced non-small-cell lung cancer: Japan Multinational Trial Organization LC00-03). J. Clin. Oncol. 24, Abstract 7013 (2006
20. Williamson SK, Crowley JJ, Lara PN Jr et al.; Southwest Oncology Group Trial S0003. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J. Clin. Oncol. 23(36), 9097-9104 (2005)